Not Yet RecruitingNot Applicable

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

South Korea6 participantsStarted 2026-06-30

Plain-language summary

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

Who can participate

Age range

50 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria * Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A. * Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements. Exclusion Criteria * Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons. * Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Safety Evaluation: Incidence of serious adverse events of special interest

Timeframe: Baseline to 5 years

Safety Evaluation: Incidence of serious adverse events (SAEs) and adverse events (AEs)

Timeframe: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in physical exams

Timeframe: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in laboratory test

Timeframe: Baseline to 5 years

Trial details

NCT IDNCT07629115

SponsorInnopeutics Corporation

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2031-06-30

Contact for this trial

ChoLong Park

+82-2-3499-4266 clpark@innopeutics.com

View on ClinicalTrials.gov More Parkinson Disease trials

Who can participate

Age range

50 Years – 80 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Safety Evaluation: Incidence of serious adverse events of special interest

Timeframe: Baseline to 5 years

Safety Evaluation: Incidence of serious adverse events (SAEs) and adverse events (AEs)

Timeframe: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in physical exams

Timeframe: Baseline to 5 years

Safety Evaluation: Number of participants with clinically-relevant changes in laboratory test

Timeframe: Baseline to 5 years